This Forum addresses the role of mitochondrial dysfunction in the multifactorial nature of diabetic cardiomyopathy (DCM) from multiple angles. Contributors deliver a diverse and in-depth view of the state-of-the-art in DCM, from bench to bedside. What emerges is a picture of mitochondrial dysfunction as a central upstream defect, inflicted on the heart by diabetes. Collectively, the authors pinpoint high-value knowledge gaps, propose new conceptual frameworks, and highlight understudied, but promising, research themes. Antioxid. Redox Signal. 22, 1499–1501.
Get full access to this article
View all access options for this article.
References
1.
ColbergSR. Exercise and Diabetes. A Clinician's Guide to Prescribing Physical Activity. Alexandria, VA: American Diabetes Association, 2013, p. 538.
2.
PicardM, ZhangJ, HancockS, DerbenevaO, GolharR, GolikP, O'HearnS, LevyS, PotluriP, LvovaM, DavilaA, LinCS, PerinJC, RappaportEF, HakonarsonH, TrounceIA, ProcaccioV, and WallaceDC. Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. Proc Natl Acad Sci U S A, 111: E4033–E4042, 2014.
3.
RublerS, DlugashJ, YuceogluYZ, KumralT, BranwoodAW, and GrishmanA. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol, 30: 595–602, 1972.
4.
StamlerJ, VaccaroO, NeatonJD, and WentworthD. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care, 16: 434–444, 1993.
5.
WestermannB. Bioenergetic role of mitochondrial fusion and fission. Biochim Biophys Acta, 1817: 1833–1838, 2012.
